Boston Scientific Corporation $BSX Stock Sold by Machina Capital S.A.S.

Machina Capital S.A.S. reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 47.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,951 shares of the medical equipment provider’s stock after selling 36,978 shares during the period. Machina Capital S.A.S.’s holdings in Boston Scientific were worth $1,788,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. BlackRock Inc. bought a new stake in Boston Scientific during the second quarter worth approximately $5,534,781,000. Primecap Management Co. CA purchased a new stake in shares of Boston Scientific during the second quarter valued at $2,156,233,000. Janus Henderson Group PLC lifted its holdings in shares of Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. Amundi boosted its position in shares of Boston Scientific by 13.8% in the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after purchasing an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Boston Scientific by 25.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after purchasing an additional 2,856,040 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $44.22 on Friday. The stock has a market cap of $64.10 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 1.34 and a beta of 0.60. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a quick ratio of 0.81, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $44.05 and a 200-day simple moving average of $54.75.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the company posted $0.75 EPS. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Sanford C. Bernstein cut their price objective on Boston Scientific from $54.00 to $49.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Wells Fargo & Company reduced their price objective on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. TD Cowen cut shares of Boston Scientific from a “buy” rating to a “hold” rating and decreased their target price for the stock from $56.00 to $46.00 in a report on Friday, October 30th. Raymond James Financial reissued an “outperform” rating and issued a $57.00 target price (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Rothschild & Co Redburn cut their price target on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.